The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

As a result, researchers have explored less invasive options that aim to treat the cancer while preserving quality of life. One such approach is TULSA, which uses real-time MRI guidance to deliver ...

First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to ...

Add Yahoo as a preferred source to see more of our stories on Google. Francis Medical’s Vanquish device for treating intermediate-risk prostate cancer has been cleared by the US Food and Drug ...

MINNEAPOLIS, Dec. 2, 2025 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company developing the breakthrough Vanquish® Water Vapor Ablation System for the management of ...

LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, and HALO ...

High-intensity focused ultrasound (HIFU) is a noninvasive way to destroy tissue or stop it from working. It was approved by the U.S. Food and Drug Administration for prostate ablation in 2015, but the ...

The 2026 European Association of Urology (EAU) annual meeting featured a late-breaking abstracts session and a presentation by Dr. Laurence Klotz discussing initial perioperative outcomes of CAPTAIN, ...

News, features, and commentary about cancer-related issues ...

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

The first prostate ablation treatment with the Ablatherm Robotic HIFU was performed at the Gramercy Surgery Center in New York. 1. Ivan Grunberger, MD, chief of urology at New York Methodist Hospital ...